Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 26 - 50 of 650 in total

Ibalizumab

Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed...
Approved
Investigational
Matched Description: … It is an advanced and current antibody in development for the treatment of HIV/AIDS. ... Ibalizumab (also known as _ibalizumab-uiyk_ and formerly known as TNX-355) is a monoclonal antibody that …
Matched Categories: … CD4-directed Blocking Antibody ... CD4-directed Antibody Interactions …

Toripalimab

The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1) - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the...
Approved
Investigational
Matched Description: … [L48681] Toripalimab is a selective, recombinant, humanized IgG4 monoclonal antibody targeted against …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody …

Nifurtimox

Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis. The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without...
Approved
Investigational

Bimekizumab

Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.[L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor,...
Approved
Investigational
Matched Description: … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in …

Isopropyl alcohol

An isomer of 1-propanol. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
Approved
Investigational
Matched Mixtures name: … ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit) …
Matched Products: … CAS Kit (COVID-19 Antibody Screening Kit) ... ACST Kit (Antibody COVID-19 Screening Test Kit) ... CAAT Kit (COVID-19 Antibody Accelerated Test Kit) …

Muromonab

Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
Approved
Investigational
Matched Description: … Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. ... More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) …
Matched Categories: … CD3-directed Antibody Interactions …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL- …

Abciximab

Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets...
Approved
Matched Description: … Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. …

Ranibizumab

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration.[A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular...
Approved
Matched Description: … Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against …

Ublituximab

CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.[A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), mediated by...
Approved
Investigational
Matched Description: … cellular cytotoxicity (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural ... [A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target ... treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody …
Matched Categories: … CD20-directed Cytolytic Antibody …

Trastuzumab deruxtecan

Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of...
Approved
Investigational
Matched Description: … [L10842] It is classified as an antibody-drug conjugate. ... Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved ... The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from …
Matched Categories: … Antibody-drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the...
Approved
Investigational
Matched Description: … Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Lanadelumab

Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical...
Approved
Investigational
Matched Description: … Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection …

Belimumab

Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A251495, L42705] By binding to...
Approved
Matched Description: … Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte …
Matched Categories: … B Lymphocyte Stimulator-directed Antibody Interactions …

Romosozumab

Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies . Romosozumab prevents bone resorption and induces the formation of bone though it is associated...
Approved
Investigational
Matched Description: … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal …

Bamlanivimab

Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to...
Approved
Investigational
Matched Description: … Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from …

Tocilizumab

Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a...
Approved
Matched Description: … Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory …

Lifileucel

Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational

Tislelizumab

Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Description: … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). ... nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Ravulizumab

Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. …

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface ... Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody …

Dupilumab

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or...
Approved
Investigational
Matched Description: … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin ... It is also being studied in combination with another antibody that which targets IL-33.[L7225] …

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved

Ramucirumab

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying drugs 26 - 50 of 650 in total